Ibritumomab tiuxetan (90y)

ZEVALIN 1,6 mg/ml, EQUIPO REACTIVO PARA LA PREPARACION DE UN RADIOFARMACO PARA PERFUSION

1,6 mg equipo de reactivos para preparación radiofarmacéuticaSpainMarketedAuthorised 17 Feb 2004

In other countries

The same active substances on other registers, the same brand first.

Packs

Pack	Code	Status
ZEVALIN 1,6 mg/ml, EQUIPO REACTIVO PARA LA PREPARACION DE UN RADIOFARMACO PARA PERFUSION, 1 equipo para preparación radiofarmacéutica	813014

Documents

The official texts, at the regulator.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Ibritumomab tiuxetan (90y)

ZEVALIN 1,6 mg/ml, EQUIPO REACTIVO PARA LA PREPARACION DE UN RADIOFARMACO PARA PERFUSION

1,6 mg equipo de reactivos para preparación radiofarmacéuticaSpainMarketedAuthorised 17 Feb 2004

Product informationAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Packs

Pack	Code	Status
ZEVALIN 1,6 mg/ml, EQUIPO REACTIVO PARA LA PREPARACION DE UN RADIOFARMACO PARA PERFUSION, 1 equipo para preparación radiofarmacéutica	813014

Documents

The official texts, at the regulator.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Summary of product characteristicsAEMPS

Package leafletAEMPS

Register entryAEMPS

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

Agencia Española de Medicamentos y Productos Sanitarios

Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.

Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required · Added 12 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Ibritumomab tiuxetan (90y)
Strength: 1,6 mg
Dosage form: equipo de reactivos para preparación radiofarmacéutica
Route: vía intravenosa
Register: Spain (AEMPS)
Status: Marketed
Status in the register: Autorizado, comercializado
Authorised: 17 Feb 2004
Registration: 03264001
Marketing authorisation holder: Ceft Biopharma S.R.O.
Procedure: EU centralised
Supply: Uso Hospitalario